Activation of the Innate Immune Checkpoint CLEC5A on Myeloid Cells in the Absence of Danger Signals Modulates Macrophages' Function but Does Not Trigger the Adaptive T Cell Immune Response.


Journal

Journal of immunology research
ISSN: 2314-7156
Titre abrégé: J Immunol Res
Pays: Egypt
ID NLM: 101627166

Informations de publication

Date de publication:
2022
Historique:
received: 18 03 2021
revised: 30 11 2021
accepted: 09 02 2022
entrez: 7 3 2022
pubmed: 8 3 2022
medline: 5 4 2022
Statut: epublish

Résumé

C-Type lectin receptor 5A (CLEC5A) is a spleen tyrosine kinase- (Syk-) coupled pattern recognition receptor expressed on myeloid cells and involved in the innate immune response to viral and bacterial infections. Activation of the CLEC5A receptor with pathogen-derived antigens leads to a secretion of proinflammatory mediators such as TNF-

Identifiants

pubmed: 35252461
doi: 10.1155/2022/9926305
pmc: PMC8896916
doi:

Substances chimiques

CLEC5A protein, human 0
Cytokines 0
Lectins, C-Type 0
Receptors, Cell Surface 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

9926305

Informations de copyright

Copyright © 2022 Milena J. Tosiek et al.

Déclaration de conflit d'intérêts

MJT, KG, AP, and EB are regular employees of Boehringer Ingelheim Pharma GmbH & Co. KG. The authors have no financial or other conflicts to declare.

Références

J Virol. 2016 Dec 16;91(1):
pubmed: 27795434
J Immunother Cancer. 2019 May 28;7(1):140
pubmed: 31138333
J Immunol. 2016 Apr 15;196(8):3227-31
pubmed: 26927798
J Immunol. 2017 Mar 1;198(5):2070-2081
pubmed: 28093525
Sci Rep. 2016 Aug 26;6:32000
pubmed: 27561946
Front Cell Dev Biol. 2021 Oct 12;9:746932
pubmed: 34712666
J Cell Biochem. 2019 Mar;120(3):2756-2765
pubmed: 30270458
Life Sci. 2019 May 1;224:222-231
pubmed: 30928403
PLoS Pathog. 2012;8(4):e1002655
pubmed: 22536153
J Leukoc Biol. 2009 Mar;85(3):508-17
pubmed: 19074552
Front Immunol. 2014 Oct 07;5:491
pubmed: 25339958
Blood. 2013 Jan 3;121(1):95-106
pubmed: 23152543
Adv Exp Med Biol. 2020;1204:57-73
pubmed: 32152943
PLoS One. 2014 Jan 21;9(1):e86105
pubmed: 24465901
J Immunol Res. 2020 Apr 23;2020:9473497
pubmed: 32377540
J Clin Invest. 2011 Nov;121(11):4446-61
pubmed: 22005300
Immunobiology. 2014 Sep;219(9):695-703
pubmed: 24916404
PLoS One. 2016 Nov 10;11(11):e0166474
pubmed: 27832191
Biochem Biophys Res Commun. 2020 Apr 9;524(3):656-662
pubmed: 32033754
J Comput Biol. 2020 Jul;27(7):1104-1114
pubmed: 31725318
Cancer Gene Ther. 2020 Sep;27(9):669-679
pubmed: 31591460
Nat Commun. 2019 Jun 3;10(1):2402
pubmed: 31160588
J Exp Med. 2010 Mar 15;207(3):579-89
pubmed: 20212065
Mol Immunol. 2011 Jan;48(4):714-9
pubmed: 21094529
Nat Commun. 2017 Aug 21;8(1):299
pubmed: 28824166
J Leukoc Biol. 2015 Oct;98(4):453-66
pubmed: 25877931
Science. 2014 Nov 28;346(6213):1258096
pubmed: 25430774
Immunobiology. 2008;213(9-10):701-13
pubmed: 18926286
Nature. 2008 May 29;453(7195):672-6
pubmed: 18496526

Auteurs

Milena J Tosiek (MJ)

Cancer Immunology & Immune Modulation, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88397 Biberach an der Riss, Germany.

Kerstin Groesser (K)

Cancer Immunology & Immune Modulation, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88397 Biberach an der Riss, Germany.

Anton Pekcec (A)

Research Beyond Borders, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88397 Biberach an der Riss, Germany.

Monika Zwirek (M)

Medical Research Council (MRC), Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK.

Gavuthami Murugesan (G)

Medical Research Council (MRC), Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK.

Eric Borges (E)

Cancer Immunology & Immune Modulation, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88397 Biberach an der Riss, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH